Rocket One Inc. Payments to Acquire in Process Research and Development
Rocket One Inc. (RKTO) reported Payments to Acquire in Process Research and Development of $74.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2024-03-28
- Rocket One Inc. payments to acquire in process research and development for the quarter ending 2022-12-31 was $7.50K, a 57.07% decline year-over-year.
- Rocket One Inc. payments to acquire in process research and development for the quarter ending 2022-09-30 was -$9.95K, a 110.87% decline year-over-year.
- Rocket One Inc. payments to acquire in process research and development for the quarter ending 2022-06-30 was $51.45K.
- Rocket One Inc. payments to acquire in process research and development for the quarter ending 2022-03-31 was $25.00K, a 64.05% decline year-over-year.
- Rocket One Inc. payments to acquire in process research and development for fiscal 2022 was $74.00K, a 36.74% decline from fiscal 2021.
- Rocket One Inc. payments to acquire in process research and development for fiscal 2021 was $116.97K, a 30.15% decline from fiscal 2020.
- Rocket One Inc. payments to acquire in process research and development for fiscal 2020 was $167.46K, a 76.27% increase from fiscal 2019.
- Rocket One Inc. payments to acquire in process research and development for fiscal 2019 was $95.00K.
| Period end | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 8 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $7.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$2.45K derived: sum of 2 quarters · filed 2024-03-28 | $49.00K derived: sum of 3 quarters · filed 2024-03-28 | $74.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$9.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $41.50K derived: sum of 2 quarters · filed 2023-11-13 | $66.50K 10-Q · filed 2023-11-13 | $83.97K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $51.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $76.45K 10-Q · filed 2023-08-11 | $93.92K derived: sum of 3 quarters · filed 2023-08-11 | $185.53K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $25.00K 10-Q · filed 2023-05-15 | $42.47K derived: sum of 2 quarters · filed 2023-05-15 | $134.07K derived: sum of 3 quarters · filed 2023-05-15 | $72.42K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $17.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $109.07K derived: sum of 2 quarters · filed 2023-03-31 | $47.42K derived: sum of 3 quarters · filed 2023-03-31 | $116.97K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $91.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $29.95K derived: sum of 2 quarters · filed 2022-11-10 | $99.50K 10-Q · filed 2022-11-10 | $159.46K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$61.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $7.90K 10-Q · filed 2022-08-12 | $67.85K derived: sum of 3 quarters · filed 2022-08-12 | $97.85K derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $69.55K 10-Q · filed 2022-05-12 | $129.50K derived: sum of 2 quarters · filed 2022-05-12 | $159.50K derived: sum of 3 quarters · filed 2022-05-12 | $197.17K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $59.96K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $89.96K derived: sum of 2 quarters · filed 2022-03-30 | $127.63K derived: sum of 3 quarters · filed 2022-03-30 | $167.46K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $67.67K derived: sum of 2 quarters · filed 2021-11-10 | $107.50K 10-Q · filed 2021-11-10 | $132.50K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $37.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $77.50K 10-Q · filed 2021-08-11 | $102.50K derived: sum of 3 quarters · filed 2021-08-11 | $152.50K derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $39.83K 10-Q · filed 2021-05-13 | $64.83K derived: sum of 2 quarters · filed 2021-05-13 | $114.83K derived: sum of 3 quarters · filed 2021-05-13 | $124.83K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $75.00K derived: sum of 2 quarters · filed 2021-03-16 | $85.00K derived: sum of 3 quarters · filed 2021-03-16 | $95.00K 10-K · filed 2021-03-16 | |
| 2019-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $60.00K derived: sum of 2 quarters · filed 2020-11-10 | $70.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $20.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $10.00K 10-Q · filed 2020-05-13 | ||||
| 2017-12-31 | $300.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |